For more information, please contact: Confo Therapeutics Dr. Cedric Ververken, CEO + 32 (0) 9 396 74 00 [email protected] Trophic Communications Valeria Fisher or Desmond James +49 (0 ...

Confo Therapeutics is a clinical-stage biotechnology company committed to identifying and accelerating novel medicines targeting GPCRs (G protein-coupled receptors).

Eli Lilly sees potential in the non-opioid pain drug research from Confo Therapeutics and it’s paying $40 million for rights to the biotech’s most advanced program. The sum is an upfront payment.

Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), today announced a publication in Nature Communications demonstrating the world’s ...

Eli Lilly will take the baton on developing a peripheral pain candidate from Confo Therapeutics, handing off $40 million upfront and a potential $590 million total down the track if all goes well.

Confo Therapeutics, a Belgian firm developing small molecules and antibodies that target G protein–coupled receptors, aims to start testing its drug candidates in humans with the help of $65 ...

GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Stephen Dowd, PhD, ...

Eli Lilly reached a deal with Confo Therapeutics to gain licensing to Confo’s non-opioid neuropathic pain candidate, CFTX-1554, the companies announced Thursday. In the deal, Confo will receive $630 ...

Confo Therapeutics NV is banking an up-front payment of $40 million from a licensing deal with Eli Lilly and Co. involving its lead asset, CFTX-1554, an oral inhibitor of the angiotensin II type 2 ...

GHENT, Belgium, March 28, 2024--Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 ...

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that its Scientific Founder and Scientific Advisory Board Chairman, Professor ...

GHENT, Belgium, July 26, 2024--Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the closing of a ...